Pfizer looks to revive Exubera with DTC

Share this article:
Pfizer will mount a branded DTC advertising campaign behind Exubera as it attempts to turn around the “disappointing” sales of the inhaled insulin product.

“While we remain convinced that Exubera offers substantial benefit for diabetic patients worldwide, we are disappointed with the product’s performance to date,” Pfizer CEO Jeff Kindler said during a conference call with analysts.

As a result, Pfizer will initiate a “full-court press” behind the product, said president, worldwide pharmaceutical operations Ian Read.

Earlier this month, Pfizer’s cardiovascular sales force began supporting the inhaled insulin.
Consumer work will launch in the second half of 2007, “when we feel it’s the right time,” Read said. “Right now we are really focused on watching the product grow.”

In February, Read told Bloomberg News that Pfizer planned a DTC ad campaign targeting newly diagnosed diabetics who may not want to inject themselves daily.

“The heart of the issue in diabetes therapy is the delay in getting patients to begin taking insulin, a delay that often lasts more than eight years.” Read said.

However, Exubera has gone largely spurned by diabetes specialists so far.

Although Pfizer has declined to make public its sales figures for Exubera, most estimates find the inhaled insulin product generated only about $5 million in sales for 2006, or one-tenth as much as much as some analysts initially forecasted.

Exubera was approved by the FDA in February 2006 but experienced a delayed launch due to manufacturing setbacks.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...